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isolation, as required by microbiological criteria, was not 
possible because a second sputum sample was unavailable.
M. sherrisii is a relatively new species (6), closely re-
lated to M. simiae. Although most of the rare M. sherrisii 
infections reported since 2004 (online Technical Appendix 
Table 1, http://wwwnc.cdc.gov/EID/article/21/11/14-1809-
Techapp1.pdf) were diagnosed in Europe or the United 
States, about half of the strains were isolated from patients 
in Africa. Because M. sherrisii infection probably is further 
underestimated by being misidentified as M. simiae infec-
tion by the commercially available line probe assays, the 
hypothesis that M. sherrisii infection is not so infrequent 
in the African setting seems therefore reasonable. In addi-
tion, the strategy recommended by World Health Organiza-
tion and based on use of immunochromatographic tests (7), 
does not enable NTM identification. A leitmotiv of most 
M. sherrisii infections reported to date is HIV co-infection, 
which leads to dissemination of the mycobacterial disease. 
This report, although it adds to the record of patients 
in Africa, does not support the association with HIV in-
fection. Our findings are consistent with the view that the 
pathogenic potential of M. sherrisii is comparable to that 
of other well-known NTM species (e.g., MAC) responsible 
for disease both in HIV-positive and HIV-negative patients. 
The retrospective determination of the MICs of antimicro-
bial agents potentially active against slowly growing my-
cobacteria (online Technical Appendix Table 2) confirmed, 
for the 4 strains of M. sherrisii, the well-known multidrug 
resistance of the species (8). The therapeutic failure was 
thus not surprising because clarithromycin was the only 
drug among those administered during the treatment that 
had been shown to be active in vitro. This report provides 
evidence that conducting appropriate microbiological in-
vestigations is essential before initiating a treatment with 
second-line TB drugs (9).
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To the Editor: In HIV-infected persons in Cameroon 
(Central Africa), histoplasmosis is still misdiagnosed as 
tuberculosis because of clinical similarities (1,2). These 
patients are automatically given presumptive antitubercu-
lous therapy, although tuberculosis is not confirmed. The 
patients subsequently die of probable disseminated histo-
plasmosis (DH), and the fungal infection might finally be 
detected in postmortem tissue samples (3). In this context, 
3 cases of DH were detected in HIV-infected patients with-
in a 1-year period (2007–2008) in Yaoundé, Cameroon. We 
initiated this study to investigate the occurrence of histo-
plasmosis in HIV-infected patients in 4 medical centers for 
AIDS treatment in Yaoundé from December 2008 through 
December 2011.
We recruited patients with known HIV status who 
agreed to participate in the study. Inclusion criteria were 
CD4 cells <200/mm3, fever and cough of >2 weeks’ 
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duration, weight loss, asthenia, and histoplasmosis-like skin 
manifestations (i.e., ulcerative lesions and/or umbilicated 
papules or nodules and/or pustules). Patients under effective 
antituberculous therapy or antimicrobial drugs for any skin 
or pulmonary infectious disease were excluded from the 
study. CD4 cell counts were performed in all patients. His-
toplasmosis was diagnosed in sputum, bronchoalveolar fluid 
(BALF), and bronchial and skin biopsies by direct staining 
with Gomori’s methenamine silver and periodic acid Schiff 
stains and by culture of sputum and BALF samples on Sab-
ouraud medium. Tuberculosis and bacterial infections were 
detected in sputum and BALF by using Ziehl-Neelsen and 
Gram staining and culture on Lowenstein-Jensen and Strep-
tococcus pyogenes media. All laboratory examinations were 
performed at the Centre Pasteur du Cameroun in Yaoundé. 
Data were collected on an anonymous questionnaire. Means 
(and SDs) were calculated for quantitative variables, and 
frequencies were calculated for qualitative variables. The 
National Ethics Committee, the Ministry of Health of Cam-
eroon, and the medical centers where the study took place 
approved the study. Patients approved and signed the in-
formed consent form at the time of recruitment.
Our study comprised 56 patients. Histoplasma capsu-
latum was detected in 7 (13%) patients on 6 of 7 skin bi-
opsies and 1 of 3 bronchial biopsies. The median CD4 cell 
count of H. capsulatum–positive patients was 40 cells/mm3. 
Similarly, some authors have reported diagnosis of severe 
DH by using direct staining of skin samples (4); in low-
income countries, skin involvement is the main presenta-
tion of DH because of limited laboratory facilities and/or 
late diagnosis. In Cameroon until recently, all DH cases in 
HIV-infected persons were diagnosed by skin biopsy or by 
chance on peripheral blood smear, thus revealing AIDS at 
the terminal stage (3,5). We did not detect H. capsulatum 
infection in sputum or BALF. These results are congruent 
with findings in Abidjan, Côte d’Ivoire, in 1999 (6). African 
histoplasmosis was not detected in any sample; although this 
type is endemic to areas with high rates of HIV infection, it 
is infrequently associated with AIDS patients (7).
We detected Mycobacterium tuberculosis in 18 (32%) 
patients and Candida albicans in 14 (25%) patients; 3 
(0.5%) patients were co-infected with M. tuberculosis and 
C. albicans. M. tuberculosis was detected in sputum of 9 
(21%) of 42 patients and in BALF of 9 (53%) of 17 pa-
tients; we detected C. albicans in sputum of 13 (31%) pa-
tients. Our detection of M. tuberculosis in 32% of patients 
confirms tuberculosis as the main AIDS-defining illness in 
Cameroon. We did not find tuberculosis and histoplasmo-
sis co-infection, even though it occurs frequently in low-
income countries (1,8).
The limitation in our study was the unavailability of 
validated sensitive and specific tools for diagnosing histo-
plasmosis in Cameroon (e.g., detection of the H. capsulatum 
circulating antigen in body fluid using an enzyme immuno-
assay) (9). Thus, using direct staining methods and culture 
of biopsies and body fluid samples could possibly lead to 
false-negative results.
Our detection of H. capsulatum in 13% of the HIV-
infected patients in this study suggests that histoplasmosis 
is an unknown public health problem in Cameroon that is 
misdiagnosed as tuberculosis. Accounting for the endemic-
ity of tuberculosis, which is the main HIV-defining illness 
in Cameroon, and the fatal outcome of DH in HIV-infected 
patients, practitioners need a high index of awareness to 
differentiate between tuberculosis and histoplasmosis. A 
recent report showed major clinical and biologic factors 
discriminating between these infections (10). Knowing 
these factors may lead practitioners to early diagnosis and 
treatment of histoplasmosis and in turn reduce the death 
rate among HIV-infected patients.
Acknowledgments
We thank Omer Njajou for statistical analysis of data.
This study was financially supported by the Réseau International 
des Instituts Pasteur.
References
  1. Couppié P, Aznar C, Carme B, Nacher M. American histoplasmosis 
in developing countries with a special focus on patients with HIV: 
diagnosis, treatment, and prognosis. Curr Opin Infect Dis. 2006; 
19:443–9. http://dx.doi.org/10.1097/01.qco.0000244049.15888.b9
  2. Jeong HW, Sohn JW, Kim MJ, Choi JW, Kim CH, Choi SH, et al. 
Disseminated histoplasmosis and tuberculosis in a patient with HIV 
infection. Yonsei Med J. 2007;48:531–4. http://dx.doi.org/10.3349/
ymj.2007.48.3.531
  3. Mandengue CE, Lindou J, Mandeng N, Takuefou B, Nouedoui C, 
Atangana P, et al. Fatal miliary tuberculosis in an HIV-infected 
Cameroon woman: disseminated histoplasmosis due to  
Histoplasma capsulatum capsulatum [in French].  
Med Trop (Mars). 2011;71:615–7.
  4. Couppié P, Clyti E, Nacher M, Aznar C, Sainte-Marie D, Carme B,  
et al. Acquired immunodeficiency syndrome–related oral/or 
cutaneous histoplasmosis. a descriptive study of 21 cases in French 
Guiana. Int J Dermatol. 2002;41:571–6. http://dx.doi.org/10.1046/
j.1365-4362.2002.01590.x
  5. Mandengue Ebenye C. A case of disseminated histoplasmosis 
detected in peripheral blood smear staining revealing AIDS at 
terminal phase in female patient from Cameroon. Case Rep Med. 
2012;2012:215207.
  6. Adou-Bryn KD, Ouhon J, Assoumou A, Kassi EA, Kone M, 
Therizol-Ferly M. Champignons et parasites isolés à l’examen  
de 142 liquides d’aspiration bronchique à Abidjan (Côte d’Ivoire). 
Med Afr Noire. 1999;46:362–5.
  7. Loulergue P, Bastides F, Baudouin V, Chandenier J,  
Mariani-Kurkdjian P, Dupont B, et al. Literature review and case 
histories of Histoplasma capsulatum var. duboisii infections in 
HIV-infected patients. Emerg Infect Dis. 2007;13:1647–52.  
http://dx.doi.org/10.3201/eid1311.070665
  8. Agudelo CA, Carlos A, Restrepo CA, Molina DA, Tobón AM, 
Kauffman CA, et al. Tuberculosis and histoplasmosis co-infection 
in AIDS patients. Am J Trop Med Hyg. 2012;87:1094–8.  
http://dx.doi.org/10.4269/ajtmh.2012.12-0292
  9. Adenis AA, Aznar C, Couppié P. Histoplasmosis in HIV-infected 
patients: a review of new developments and remaining gaps.  
Curr Trop Med Rep. 2014;1:119–28.
10. Adenis A, Nacher M, Hanf M, Basurko C, Dufour J, Huber F, et al. 
Tuberculosis and histoplasmosis among human immunodeficiency 
virus–infected patients: a comparative study. Am J Trop Med Hyg. 
2014;90:216–23. http://dx.doi.org/10.4269/ajtmh.13-0084
Address for correspondence: Christine E. Mandengue, Department of 
Internal Medicine (Dermatology), Université des Montagnes, Cliniques 
Universitaires des Montagnes, PO Box 208, Bangangté, Cameroon; 
email: cmmandengue@udesmontagnes.org
Divergent Gemycircularvirus 
in HIV-Positive Blood, France
Rathviro Uch, Pierre-Edouard Fournier,  
Catherine Robert, Caroline Blanc-Tailleur, 
Vital Galicher, Romain Barre, François Jordier, 
Philippe de Micco, Didier Raoult, Philippe Biagini
Author affiliations: Centre National de la Recherche Scientifique, 
Marseilles (R. Uch, P.-E. Fournier, C. Robert, C. Blanc-Tailleur,  
V. Galicher, R. Barre, F. Jordier, P. de Micco, D. Raoult, P. Biagini); 
Institut Hospitalo-Universitaire Méditerranée-Infection, Marseille, 
France (R. Uch, P.-E. Fournier, C. Robert, C. Blanc-Tailleur,  
R. Barre, F. Jordier, P. de Micco, D. Raoult, P. Biagini);  
Aix-Marseille Université, Marseille (R. Uch, P.-E. Fournier,  
C. Robert, C. Blanc-Tailleur, V. Galicher, R. Barre, F. Jordier,  
P. de Micco, D. Raoult, P. Biagini); Unité Mixte de Recherche 7268 
ADES, Marseilles (R. Uch, V. Galicher, R. Barre, F. Jordier,  
P. de Micco, P. Biagini); Etablissement Français du Sang,  
Marseilles (R. Uch, V. Galicher, R. Barre, F. Jordier, P. de Micco, 
P. Biagini); Unité de Recherche sur les Maladies Infectieuses  
et Tropicales Emergentes, Marseilles (P.-E. Fournier, C. Robert, 
C. Blanc-Tailleur, D. Raoult)
DOI: http://dx.doi.org/10.3201/eid2111.150486
To the Editor: Gemycircularviruses are a group of 
recently discovered single-stranded DNA viruses, found 
initially in fungi in 2010 (1). These “myco-like” virus-
es have a genome ranging from 2.1 to 2.3 kb, contain-
ing 2 opposite open reading frames that probably code 
for a capsid protein (CP) and a spliced replication-as-
sociated protein (Rep). Related viruses have been sub-
sequently identified in animal blood and fecal matter, 
raw and treated sewage, and insects and plant material, 
suggesting that gemycircularviruses may represent a 
large group of viruses exhibiting considerable genetic 
diversity (2–8). The presence of these viruses was re-
cently extended to humans after gemycircularvirus se-
quences were identified in human blood and brain tissue 
(multiple sclerosis patient), cerebrospinal fluid, and fe-
cal matter (8,9).
While investigating the virome content of an HIV-pos-
itive blood donation, we identified several gemycircular-
virus-related sequences. The initial metagenomic approach 
involved an HIV-1–positive plasma sample (B genotype, 
≈530 copies/mL) obtained from the French blood agency 
national plasma bank in Tours, France. A 4-mL aliquot was 
prepared for metagenomic analysis after filtration, concen-
tration, and nucleases treatment. Next, particle-protected 
nucleic acids were recovered and used for the preparation 
of a next-generation sequencing library and its subsequent 
analysis (online Technical Appendix, http://wwwnc.cdc.
gov/EID/article/21/11/15-0486-Techapp1.pdf). Gemycir-
cularvirus sequences identified among reads (1,680 vs. 
82,560 reads total; ≈2%) were assembled into a resulting 
full-length sequence (GemyC1c) by using CodonCode 
Aligner version 5.1 (CodonCode Corporation, Centerville, 
MA, USA). This sequence was verified by using back-to-
back specific primers, and the amplicon was cloned and 
sequenced according to the Sanger method.
The analysis of the GemyC1c sequence (2,109 nt, Gen-
Bank accession no. KP987887) revealed a genome divergent 
from those already available in databases, despite a similar 
genomic organization (Figure, panel A) and assignment to 
gemycircularviruses after BLAST (http://blast.ncbi.nlm.nih.
gov/Blast.cgi) analysis of putative CP and Rep proteins. This 
divergence was demonstrated by the phylogenetic analysis 
of the deduced CP (Figure, panel B), which exhibited ≈72% 
and ≈44% aa pairwise identity with the 2 closest gemycir-
cularvirus CP sequences available in GenBank (gemycir-
cularvirus c from mongoose feces [Conceicao-Neto N., un-
pub. data] and HCBI8.215 from cattle blood, respectively). 
Moreover, GemyC1c CP exhibited ≈30% pairwise identity 
with viral sequences identified previously in humans (BZ1 
from feces, SL1 from cerebrospinal fluid, MSSI2.225 from 
blood). The deduced spliced Rep (major Rep1 and minor 
Rep2), seen in such viruses, contained putative rolling circle 
motifs I (LFTYS), II (HLHAFVD), and III (YATKD) re-
trieved from gemycircularviruses (4).
We subsequently investigated the presence of Ge-
myC1c DNA in 128 HIV-positive plasma samples (French 
blood agency national plasma bank) along with 256 HIV-
negative plasma samples (healthy blood donors, southeast-
ern France; mean donor age 38 years; 136 men; 1 man:1.13 
women). Plasma samples were prepared as described pre-
viously (10), and extracted nucleic acids were tested for 
GemyC1c DNA by using a specific PCR that included 
negative, positive, and extraction controls (online Techni-
cal Appendix).
Application of the above GemyC1c DNA detection 
system did not generate any positive signal in the 384 
plasma samples in this study, suggesting that the presence 
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